Breast Cancer | Unmet Need | US/EU | 2017
The HER2-positive breast cancer treatment paradigm has undergone considerable change in recent years and is expected to evolve further as more novel therapies enter the market. The enthusiastic adoption of HER2-targeting biologics, Roche/Genentech’s Perjeta (pertuzumab) and Kadcyla (T-DM1), has increased the barrier of entry for new emerging therapies. However, unmet need still exists for the treatment of advanced/metastatic HER2-positive breast cancer. Our content examines the key drivers of prescribing and analyzes the areas of significant commercial opportunities.
Questions Answered:
- What are the treatment drivers and goals for advanced/metastatic HER2-positive breast cancer?
- What attributes are key influencers, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for advanced/metastatic HER2-positive breast cancer?
- What are the prevailing areas of unmet need and opportunity in advanced/metastatic HER2-positive breast cancer?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical new, advanced/metastatic HER2-positive breast cancer drug?
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 31 European medical oncologists fielded in February 2017.
Key companies: Roche/Genentech, Novartis
Key drugs: Perjeta, Kadcyla, Tykerb/Tyverb
